AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States

/in

Tuesday, September 13, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. […]

Read more

AmpliPhi Biosciences’ Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization

/in

Monday, September 12, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted its collaborators at the University of Leicester demonstrating the therapeutic and prophylactic efficacy of AmpliPhi’s proprietary phage […]

Read more

Avita Medical’s Regenerative Skin Technology significantly reduces burn scars and healing time

/in

Northridge, CA, Perth, Australia and London, United Kingdom – 2 September 2016 Link here.

Read more

ADR – Thomas Lynch appointed as new Adherium chairman

/in

1 September 2016: Link here. Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director. Mr Lynch’s appointment follows a global search for a high profile Director with broad […]

Read more